---
title: "Advancements in ADCs for Cancer Treatment: A Hopeful Shift Towards Precision Medicine"
description: "Advancements in ADCs for Cancer Treatment: A Hopeful Shift Towards Precision Medicine"
---


:::info

"Informed AI News" is an publications aggregation platform, ensuring you only gain the most important information, to eliminate information asymmetry and break through the limits of information cocoons.  [Find out more >>](/docs/guides)

:::

# Advancements in ADCs for Cancer Treatment: A Hopeful Shift Towards Precision Medicine

import Tabs from '@theme/Tabs';
import TabItem from '@theme/TabItem';

<Tabs
	defaultValue="summary"
	values={[
	{label: 'summary', value: 'summary'},
	{label: 'score', value: 'score'},
]}>
<TabItem value="summary">


At the recent ASCO conference, attention focused on ADCsâ€”antibody-drug conjugates, a class of drugs that merge antibodies with potent chemotherapy. These agents specifically target cancer cells, minimizing damage to healthy tissues. Notably, Enhertu, developed by AstraZeneca and Daiichi Sankyo, demonstrated significant potential in prolonging survival for breast cancer patients, contributing to its $26 billion in sales.

Enhertu's success reflects a broader shift in cancer treatment towards precision medicine, which customizes therapies based on individual genetic profiles to enhance effectiveness and reduce side effects. Additionally, AstraZeneca's osimertinib and Merck & Co.'s sacituzumab govitecan-hziy also reported positive outcomes in lung cancer treatment at the conference.

The implications are significant: ADCs could transform the treatment of breast and lung cancers, which are the leading causes of cancer-related deaths worldwide. As AstraZeneca seeks regulatory approval with updated data, the prospects for these targeted therapies appear promising.

Furthermore, AstraZeneca's goal to double its revenue by 2030, along with substantial investments in manufacturing and research, highlights the company's dedication to innovation and global health. However, the withdrawal of their COVID-19 vaccine due to side effects underscores the inherent risks in pharmaceutical development.

Overall, the advancements in ADCs offer a glimmer of hope in the fight against cancer, signaling a move towards more personalized and effective treatments.
</TabItem>
<TabItem value="score">
	| Scores     | Value   | Explanation |
	| -------- | ------- | ------- |
	| Objectivity  | 5    | Content provides a balanced overview of ADC advancements, focusing on their potential benefits in cancer treatment.    |
	| Social Impact | 4     | Content discusses significant medical advancements that could influence public opinion on cancer treatment.    |
	| Credibility    | 5    | Content is based on findings from a major medical conference, enhancing its credibility.    |
	| Potential    | 5    | The discussion on ADCs has high potential to lead to significant improvements in cancer treatment.    |
	| Practicality    | 4    | The practical application of ADCs in cancer treatment is discussed, highlighting their direct applicability.    |
	| Entertainment Value    | 2    | While informative, the content lacks typical entertainment elements, focusing more on medical and scientific details.    |
</TabItem>
</Tabs>

[Full article>>](https://readhub.cn/topic/8a6dwdIGdUi)
